Kidney Cancer — Symptoms, Staging, and Surgical Options in Hyderabad
Kidney cancer is increasingly diagnosed at small, incidental sizes in India found on ultrasound or CT performed for unrelated reasons such as abdominal pain, recurrent UTI, or a routine health check-up. This incidental detection is clinically significant: a kidney tumour found at 2 to 3cm, confined to the kidney, is almost always curable. A kidney tumour found at 8 to 10cm symptomatic, locally advanced, or already spread to lymph nodes — requires far more complex treatment with a less certain prognosis. The rise of imaging availability in India means more kidney cancers are being caught early but this also means that the surgical strategy matters more than ever, because the treatment choice for a small kidney tumour determines not just cancer control but the patient's long-term kidney function.
This is where KIMS Secunderabad's robotic surgical programme makes its most clinically significant difference. The standard approach to a kidney tumour at many hospitals particularly larger tumours is radical nephrectomy: surgical removal of the entire kidney. This is simple, definitive, and surgically straightforward. It is also the wrong choice for many patients with kidney tumours that could be removed with partial nephrectomy — preserving the remaining kidney parenchyma, protecting long-term eGFR, and avoiding the cardiovascular consequences of reduced kidney function. At KIMS, robotic partial nephrectomy (RAPN) using the Da Vinci Xi and X platforms is performed for tumours where nephron-sparing is surgically achievable — preserving kidney function that radical nephrectomy would permanently destroy.
Types of kidney cancer
The vast majority of kidney cancers approximately 90% — are renal cell carcinoma (RCC), arising from the renal tubular epithelium. RCC itself has several histological subtypes with different biological behaviours:
Clear cell RCC
The most common (70 to 75% of RCC). Named for the clear cytoplasm of the tumour cells. The subtype most responsive to targeted therapies (sunitinib, pazopanib) and immunotherapy (nivolumab, pembrolizumab) in metastatic disease.
Papillary RCC
15 to 20% of RCC. Type 1 papillary is generally indolent; Type 2 papillary is more aggressive. Associated with hereditary papillary RCC syndrome.
Chromophobe RCC
5% of RCC. Generally favourable prognosis. May be associated with Birt-Hogg-Dubé syndrome.
Collecting duct carcinoma and other rare subtypes
Collectively less than 5% of RCC but with variable and sometimes aggressive behaviour.
Transitional cell carcinoma (TCC/urothelial carcinoma)
Arises from the lining of the kidney's collecting system rather than the kidney tissue itself. Biologically distinct from RCC and managed differently. Associated with smoking, analgesic nephropathy, and Lynch syndrome in some cases.
Wilms' tumour (nephroblastoma)
The most common kidney cancer in children. Managed with nephrectomy, chemotherapy, and sometimes radiotherapy through the paediatric oncology team.
Symptoms of kidney cancer — why it is usually silent
The classic triad of kidney cancer — flank pain, haematuria (blood in urine), and a palpable abdominal mass — now accounts for fewer than 10% of presentations. Most kidney cancers in 2026 are incidentally detected on imaging before any of these signs develop. When symptoms do occur:
Haematuria — visible blood in the urine. Even a single episode warrants urgent review.
Flank or back pain — dull, persistent pain on the side of the affected kidney.
Palpable mass — a lump felt in the upper abdomen or flank indicating a large tumour.
Hypertension — high blood pressure caused by renin production (Paraneoplastic).
Polycythaemia — excess red blood cell production from erythropoietin (Paraneoplastic).
Hypercalcaemia, weight loss, and fever — non-specific systemic symptoms.
Bone pain or persistent cough — potential signs of metastasis in advanced disease.
Incidental Detection — many cases are found on imaging before any symptoms develop.
PAINLESS HAEMATURIA = UROLOGICAL EMERGENCY
Visible blood in the urine even a single episode, even without pain must be investigated with urology review and imaging. Painless haematuria can indicate kidney cancer, bladder cancer, or upper urinary tract cancer. Do not assume it is a UTI without a urine culture and imaging to confirm.
Call KIMS on 040 - 44885000 for an urgent appointment.
Staging kidney cancer — how far has it spread?
Kidney cancer is staged using the TNM system — Tumour size and extension (T), lymph Node involvement (N), and distant Metastasis (M). The staging workup at KIMS determines the most effective treatment path:
| Stage | Description & Treatment Approach |
|---|---|
Stage I (T1)Tumour ≤7cm, confined to kidney | Small localised kidney cancer. Stage Ia: ≤4cm. Stage Ib: 4–7cm. Curative surgery — robotic partial nephrectomy where feasible (nephron-sparing), radical nephrectomy for complex tumours. Active surveillance for very small T1a tumours in elderly patients with significant comorbidity. |
Stage II (T2)Tumour >7cm, confined to kidney | Larger localised kidney cancer. Curative surgery — radical nephrectomy is often required, though partial nephrectomy is attempted for T2 tumours in selected cases by experienced robotic surgeons. |
Stage III (T3)Invasion of perinephric fat, renal vein, or IVC | Locally advanced. May involve venous tumour thrombus extending into the renal vein or inferior vena cava. Surgery is still curative in many cases — radical nephrectomy with thrombectomy for venous extension. Lymph node dissection. |
Stage IV (T4 or M1)Invasion beyond Gerota's fascia or distant metastasis | Advanced or metastatic disease. Systemic therapy — tyrosine kinase inhibitors (sunitinib, pazopanib, cabozantinib), mTOR inhibitors (everolimus), and immune checkpoint inhibitors (nivolumab + ipilimumab, pembrolizumab + axitinib) are standard first-line options for clear cell RCC. Cytoreductive nephrectomy considered in selected patients. |
Robotic partial nephrectomy (RAPN) — why kidney preservation matters
For tumours that can be surgically removed while preserving a meaningful portion of the kidney typically tumours below 7cm that are not centrally located in the kidney or directly adjacent to major vessels partial nephrectomy is the preferred approach. The rationale: removing an entire kidney for a tumour that could have been excised with clear margins and kidney preservation destroys functional nephrons that the patient will need for the rest of their life.
The long-term consequence of radical nephrectomy in a patient who had two functioning kidneys is a reduction in total eGFR — typically to 60 to 70% of the pre-operative baseline. For many patients, this remaining function is adequate and causes no immediate problems. But as the patient ages and particularly if they develop diabetes, hypertension, or other kidney insults over the following decades the reduced renal reserve leaves them more vulnerable to CKD progression and, ultimately, kidney failure. Patients who are 45 to 60 years old at the time of radical nephrectomy for a small kidney tumour may spend their 70s and 80s with CKD Stage 3 or 4 when they might have remained at Stage 1 or 2 with partial nephrectomy.
Robotic partial nephrectomy (RAPN) at KIMS achieves the same cancer control as radical nephrectomy for appropriately selected tumours — with negative surgical margins in over 95% of cases in high-volume robotic programmes while preserving the remaining kidney parenchyma. The Da Vinci robot's 10x magnified 3D vision allows the surgeon to identify the tumour margin precisely, excise the tumour with a thin rim of normal tissue, and repair the kidney with secure renorrhaphy — all performed laparoscopically through keyhole incisions with significantly less blood loss and faster recovery than open partial nephrectomy.
At KIMS, every kidney tumour case is assessed for robotic partial nephrectomy candidacy using the R.E.N.A.L. or PADUA nephrometry score (a standardised measurement of tumour complexity based on size, location, depth, proximity to vessels and collecting system) to determine whether RAPN is feasible and appropriate. Cases where RAPN complexity is high or where the tumour's location makes partial resection oncologically unsafe are recommended for radical nephrectomy — the goal is always the best cancer outcome, not a partial procedure for its own sake.
Why patients choose KIMS Secunderabad for kidney cancer surgery
KIMS combines advanced robotic platforms with a specialized "nephron-sparing" philosophy to ensure the best oncological outcomes while protecting long-term kidney health.
Da Vinci Xi AND Da Vinci X Platforms
KIMS operates both of the latest robotic platforms. The Xi's fourth arm and multi-quadrant reach is superior for complex RAPN cases involving the hilum or posterior tumours, while the X handles standard RAPN with equivalent precision. Having both ensures the right technology is matched to the tumour's complexity.
Nephron-sparing Philosophy
KIMS systematically assesses every kidney tumour for partial nephrectomy feasibility before recommending radical nephrectomy. While many centres default to removing the entire kidney for convenience, KIMS defaults to nephron-sparing (preserving healthy tissue) where oncologically appropriate to protect the patient's future renal reserve.
Expertise of Dr. Likhiteswer Pallagani
Led by a surgeon with 400+ robotic surgeries and a Vattikuti Foundation fellowship in uro-oncology and robotic surgery. Dr. Pallagani has authored three peer-reviewed publications, including the PRETA nephrometry score specifically designed for robotic partial nephrectomy planning.
Multidisciplinary Tumour Board (MDT)
Every kidney cancer case is reviewed by a formal panel including a urological oncologist, medical oncologist, radiologist, and pathologist. This collaborative approach ensures the treatment plan reflects collective expertise across all specialties, not just a single surgical opinion.
Integrated Nephrology Support
For patients at risk of CKD due to reduced renal reserve after surgery, the KIMS nephrology team provides seamless, long-term kidney health management within the same institution. This integrated care is critical for maintaining overall health decades after cancer treatment.
Accredited & Empanelled Care
KIMS Secunderabad is NABH and NABL accredited. We are proud to be empanelled with Aarogyasri (PMJAY), CGHS, and EHS, ensuring that advanced robotic cancer care is accessible to all segments of society with full insurance and government scheme support.
Frequently Asked Questions — Kidney Cancer
Most early kidney cancers — Stage I and Stage II tumours confined to the kidney — produce no symptoms at all. They are detected incidentally on ultrasound or CT scan performed for unrelated reasons. When symptoms do occur in early kidney cancer, they may include: haematuria (blood in the urine — even a single episode of painless haematuria warrants immediate urology investigation), dull flank or back pain on the affected side, or non-specific symptoms such as fatigue or unexplained weight loss. Any visible blood in the urine must be investigated urgently — it is never safe to assume a single episode of haematuria is a UTI without imaging to exclude a urological malignancy.
Stage I kidney cancer — tumours below 7cm confined to the kidney — is curable with surgery in the vast majority of cases. Five-year cancer-specific survival for Stage I RCC exceeds 95%. Stage II and Stage III locally advanced kidney cancer is surgically curable in many cases, with 5-year survival of 65 to 75% for Stage II and 40 to 60% for Stage III depending on the extent of local invasion. Stage IV metastatic kidney cancer is not currently curable but is increasingly manageable for years with combination immunotherapy and targeted therapy — some patients with metastatic clear cell RCC achieve durable remissions lasting many years on nivolumab plus ipilimumab.
Radical nephrectomy removes the entire kidney — together with the surrounding Gerota's fascia, perinephric fat, and sometimes the adrenal gland. It is definitive cancer surgery for large or centrally located tumours where preserving kidney tissue safely is not feasible. Partial nephrectomy removes only the tumour and a thin rim of normal kidney tissue, preserving the remaining kidney parenchyma and its long-term function. For appropriately selected tumours (typically below 7cm, not centrally located), partial nephrectomy achieves equivalent cancer control to radical nephrectomy with the significant benefit of preserved kidney function. At KIMS, robotic partial nephrectomy (RAPN) is assessed for every kidney tumour — radical nephrectomy is recommended only when partial excision is oncologically unsafe or technically not feasible.
Robotic partial nephrectomy (RAPN) at KIMS uses the Da Vinci Xi or X platform — 3 to 4 keyhole incisions of less than 1cm each, 10x magnified 3D vision of the surgical field, and 7-degree instrument freedom for precise tumour excision and kidney repair. Operating time is typically 2 to 3 hours. Blood transfusion is required in less than 5% of cases with the robotic approach. Hospital stay is 2 to 3 nights. Recovery to normal activity is 3 to 4 weeks. Robotic radical nephrectomy (RARN) follows a similar approach but involves removal of the entire kidney — recovery is similar. Open surgery requires a 15 to 20cm flank incision, 5 to 7 nights in hospital, and 4 to 6 weeks recovery.
For localised kidney cancer managed with surgery, chemotherapy is not standard. Traditional chemotherapy agents are largely ineffective in renal cell carcinoma. For metastatic kidney cancer, systemic therapy uses targeted agents (sunitinib, pazopanib, cabozantinib — which target VEGF pathway) or immune checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab — which activate the immune system to attack cancer cells). These are not chemotherapy in the conventional sense — they are molecularly targeted or immunological treatments with different mechanism, toxicity profile, and effectiveness. For Stage I to III kidney cancer after surgery, there is currently no standard adjuvant systemic therapy, although trials of pembrolizumab adjuvant therapy for high-risk disease have shown promising results.
Yes — kidney cancer (particularly clear cell RCC) can metastasise to lungs (the most common site — 50 to 60% of metastatic cases), bone, liver, brain, and lymph nodes. Metastatic spread is the reason staging workup (CT chest, abdomen, pelvis — and bone scan where indicated) is performed at the time of diagnosis. Kidney cancer is also notable for late recurrence — metastases can appear 10 or more years after apparently curative surgery. This makes long-term surveillance important: KIMS follows kidney cancer patients with CT imaging at defined intervals for 5 to 10 years after surgery, and indefinitely for higher-risk tumours.
KIMS Secunderabad — Da Vinci Xi AND X robotic platforms, systematic robotic partial nephrectomy assessment for every kidney tumour (nephron-sparing philosophy), Dr. Likhiteswer Pallagani with 400+ robotic surgeries and Vattikuti Foundation uro-oncology fellowship, multidisciplinary tumour board review, integrated nephrology for post-operative kidney function management. NABH and NABL accredited. Aarogyasri and CGHS and EHS empanelled.